ADVERSE REACTIONS RELATED TO DRUGS FOR HEADACHE TREATMENT: CLINICAL IMPACT

Abstract Objective: To assess the clinical impact of ad- verse reactions related to drugs for primary headache treatment. Methods: We examined the adverse reactions to 360 medications prescribed by the specialists of the Head- ache Centre of the University of Modena and Reggio Emilia to 256 consecutive outpatients (214 female, 42 male; mean age: 38.88±14.06 years; range 10–72 years). Adverse reactions were reported by patients during scheduled follow-up visits, classified by specialists and reassessed by a clinical pharmacologist. Results: Adverse reactions with a causal relationship classified as definite/probable/possible were 202 (56%): 62% (80/129) were due to acute treatments and 53% (122/231) to prophylactic treatments (v2 test, P= 0.115 ns). More than 90% of the adverse reactions were of limited intensity [mild (58%) or moderate (36%)]. Only 5% were severe, and two reactions (1%) were serious. The most affected apparatus was the nervous system (41%). Of these adverse reactions, 43% caused the discontinuance of the treatment, especially of pro- phylaxis (54%). Patients evaluated 70% of the medica- tions as effective, but, at the same time, they considered most of the adverse reactions (69%) unacceptable. Conclusion: Adverse reactions related to headache medications have a strong impact on patients’ manage- ment, even if their real intensity and severity are usually very limited. Drugs for headache treatment are still farfrom being ideal drugs. To prevent the discontinuance of effective medications, the physician, prior to prescribing, should assess, together with the patient, the acceptability of the more common adverse drug reactions.